The National Comprehensive Cancer Network (NCCN) guidelines for breast and ovarian cancer recommend that RRSO should be considered beginning at age 45 to 50 years in women carriers of germline variants in RAD51D. The gene discussed is RAD51D; the disease is ovarian carcinoma.